Moderna Stock Rebounds Despite Vaccine Maker's Wider-Than-Expected Loss
Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...
Moderna is counting on its product pipeline to resuscitate its ailing stock
Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...
FOX 5 Atlanta21h
Measles outbreaks: Here's who should get a booster shot
As public health officials monitor a rise in U.S. measles cases, some may be wondering if they need a booster vaccine to ...
Health on MSN21h
Do You Need a Measles Booster? Here’s What Experts Recommend
With cases of measles—a highly contagious virus—popping up across the country, you might be wondering if you need another ...
US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...